SynthesisBMC pharmacology & toxicology2026
Effect of oral semaglutide on cardiometabolic risk factors in overweight and obese individuals with or without diabetes: a systematic review and meta-analysis.
Synthesis in BMC pharmacology & toxicology, 2026. The graph read 1 number from its abstract, feeding 1 cell of the map: it supports the treatment in 1. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
Semaglutide also showed a protective effect on cardiovascular events (OR = 0.64; p = 0.006).
clause the extractor read what became the number
Where it lands on the map
Rows are treatments, columns are outcomes. The coloured squares are the cells this paper feeds, coloured by the vote it casts there. Click one to jump to what this paper adds to it.
What it adds to each cell
For every cell the paper feeds: the belief in the claim with and without this paper, and this paper's estimate drawn against every other readable study in the cell. The ringed dot is this paper.
GLP-1 receptor agonists×cardiovascular events
SupportsOpen on the map →What to test next →13 readable studies in this cell: 7 favour the treatment, 2 find no difference, 4 favour the comparator.
This paper's own estimate is on a different scale from the rest of the cell, so it is not drawn here.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Combined Treatment of Type 2 Diabetes and Hypothyroidism: Impact of Oral Semaglutide and Levothyroxine on Cardiometabolic and Thyroid Parameters: A 6-Month Comparative Study.Epidemiologia (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The marked sentences are the ones the graph read a number from.
backgroundObesity is linked to cardiometabolic risk, and semaglutide, a glucagon-like peptide-1 receptor agonist, has emerged as a promising option for weight and metabolic control. This systematic review and meta-analysis evaluated the effects of oral semaglutide, compared with placebo, on cardiometabolic risk factors in overweight and obese adults with or without diabetes. MATERIALS AND
methodsIn this systematic review and meta-analysis, following PRISMA 2020 guidelines, PubMed, Embase, and Scopus were searched through 25 August 2025. Randomized controlled trials (RCT) with overweight and obese populations, with or without diabetes, were included. The treatment and control groups received oral semaglutide and placebo, respectively. Outcomes were cardiometabolic factors and adverse events at baseline and follow-up. We pooled data using a random-effects model to estimate changes in outcomes by reporting Estimated Treatment Difference (ETD) as mean difference. Subgroup analyses were conducted based on dosage and follow-up duration.
resultsThirteen RCTs involving 26,284 participants met the criteria (52% received semaglutide). Female ratio of the semaglutide group was 30.1% and for the placebo group weas 33.3%. Compared with placebo, semaglutide showed significant reductions in body weight (ETD - 2.85 kg; 95% CI [- 4.03 to - 1.66]; p < 0.001), BMI (ETD - 0.66 kg/m²; 95% CI [- 0.95 to - 0.36]; p < 0.001), waist circumference (ETD - 1.79 cm; 95% CI [- 2.63 to - 0.95]; p < 0.001), HbA1c (ETD - 0.94%; 95% CI [- 1.13 to - 0.76]; p < 0.001), fasting plasma glucose (ETD - 26.91 mg/dL; 95% CI [- 33.56 to - 20.26]; p < 0.001), systolic blood pressure (ETD - 2.71 mmHg; 95% CI [- 3.70 to - 1.72]; p < 0.001), and diastolic blood pressure (ETD - 0.77 mmHg; 95% CI [- 1.38 to - 0.17]; p = 0.01) over 6 months. Benefits were consistent across different follow-up durations and doses. Gastrointestinal symptoms remained the most common adverse events (OR for GI issues = 2.69; nausea = 3.13; vomiting = 6.25; all p < 0.001). Semaglutide also showed a protective effect on cardiovascular events (OR = 0.64; p = 0.006).
conclusionOral semaglutide demonstrates meaningful improvements in cardiometabolic outcomes and a favorable safety profile, supporting its use as a non-invasive therapy for obesity and related metabolic disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.